Immunomodulatory regulator blockade in a viral exacerbation model of severe asthma.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 21 06 2022
accepted: 03 11 2022
entrez: 8 12 2022
pubmed: 9 12 2022
medline: 15 12 2022
Statut: epublish

Résumé

Asthmatics are more susceptible to viral infections than healthy individuals and are known to have impaired innate anti-viral defences. Influenza A virus causes significant morbidity and mortality in this population. Immuno-modulatory regulators (IMRs) such as PD-1 are activated on T cells following viral infection as part of normal T cell activation responses, and then subside, but remain elevated in cases of chronic exposure to virus, indicative of T cell exhaustion rather than activation. There is evidence that checkpoint inhibition can enhance anti-viral responses during acute exposure to virus through enhancement of CD8+T cell function. Although elevated PD-1 expression has been described in pulmonary tissues in other chronic lung diseases, the role of IMRs in asthma has been relatively unexplored as the basis for immune dysfunction. We first assessed IMR expression in the peripheral circulation and then quantified changes in IMR expression in lung tissue in response to ex-vivo influenza infection. We found that the PD-1 family members are not significantly altered in the peripheral circulation in individuals with severe asthma but are elevated in pulmonary tissues following ex-vivo influenza infection. We then applied PD-1 Mab inhibitor treatment to bronchial biopsy tissues infected with influenza virus and found that PD-1 inhibition was ineffective in asthmatics, but actually increased infection rates in healthy controls. This study, therefore, suggests that PD-1 therapy would not produce harmful side-effects when applied in people with severe asthma, but could have important, as yet undescribed, negative effects on anti-viral responses in healthy individuals that warrant further investigation.

Identifiants

pubmed: 36479132
doi: 10.3389/fimmu.2022.973673
pmc: PMC9720166
doi:

Substances chimiques

Programmed Cell Death 1 Receptor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

973673

Informations de copyright

Copyright © 2022 Nicholas, Lee, Guo, Cicmil, Blume, Malefyt and Djukanović.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This work was supported by a collaboration between the University of Southampton and Merck & Co Inc. Merck & Co Inc. assisted in the design of the work and the collection, analysis, and interpretation of data. The manuscript was conceived and written by the University of Southampton co-authors and was approved by co-authors from Merck & Co Inc.

Références

Mol Med Rep. 2016 Aug;14(2):1107-16
pubmed: 27314219
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
J Immunol. 2002 Nov 15;169(10):5538-45
pubmed: 12421930
Cell Death Dis. 2016 Feb 25;7:e2115
pubmed: 26913605
PLoS Pathog. 2022 Jan 20;18(1):e1009894
pubmed: 35051231
J Immunol. 2020 Mar 1;204(5):1242-1254
pubmed: 31988180
PLoS One. 2014 Aug 21;9(8):e105703
pubmed: 25144233
J Allergy Clin Immunol. 2012 Jun;129(6):1506-1514.e6
pubmed: 22657407
Gastroenterology. 2010 Feb;138(2):682-93, 693.e1-4
pubmed: 19800335
Immun Inflamm Dis. 2020 Sep;8(3):310-319
pubmed: 32394602
Am J Respir Crit Care Med. 2016 Mar 15;193(6):642-51
pubmed: 26517304
Front Immunol. 2020 Mar 24;11:487
pubmed: 32265932
Am J Respir Crit Care Med. 2010 May 15;181(10):1049-60
pubmed: 20110559
J Immunol. 2015 Jun 15;194(12):6144-54
pubmed: 25934861
PLoS Pathog. 2009 Feb;5(2):e1000313
pubmed: 19247441
Clin Exp Allergy. 2017 Nov;47(11):1417-1425
pubmed: 28865147
J Leukoc Biol. 2011 Apr;89(4):507-15
pubmed: 21097698
J Allergy Clin Immunol. 2017 Jul;140(1):309-312.e4
pubmed: 28259448
Blood. 2010 Oct 28;116(17):3311-20
pubmed: 20625006
Mucosal Immunol. 2013 Jul;6(4):797-806
pubmed: 23212197
Gastroenterology. 2008 Jun;134(7):1927-37, 1937.e1-2
pubmed: 18549878
Sci Rep. 2019 Nov 21;9(1):17252
pubmed: 31754127
Nat Rev Immunol. 2018 Feb;18(2):91-104
pubmed: 28990586
J Infect Dis. 2006 Feb 1;193(3):404-12
pubmed: 16388488
J Hepatol. 2014 Dec;61(6):1212-9
pubmed: 25016223
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6303-8
pubmed: 19332785
Thorax. 2008 May;63 Suppl 4:iv1-121
pubmed: 18463203
J Immunol. 2015 May 1;194(9):4545-54
pubmed: 25810391
Sci Rep. 2016 Dec 07;6:38362
pubmed: 27924827

Auteurs

Ben Nicholas (B)

Division of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Hampshire, United Kingdom.

Hyun-Hee Lee (HH)

Oncology & Immunology Discovery, Merck Research Laboratories, Boston, MA, United States.

Jane Guo (J)

Oncology & Immunology Discovery, Merck Research Laboratories, Boston, MA, United States.

Milenko Cicmil (M)

Oncology & Immunology Discovery, Merck Research Laboratories, Boston, MA, United States.

Cornelia Blume (C)

Division of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Hampshire, United Kingdom.

René De Waal Malefyt (RW)

Merck Research Laboratories, Palo Alto, CA, United States.

Ratko Djukanović (R)

Division of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Hampshire, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH